Kevin Patrick Danahy sold $1.4M of PLSE
Chief Commercial Officer at Pulse Biosciences, Inc.. 60,000 shares at an average of $23.39, traded Feb 9, 2026, filed Feb 11, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 95% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.6%, 3m -5.1%, 6m +71.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-003840, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -20,000 | $21.45 | $429k | 43,298 | Feb 11, 2026 |
| Feb 10, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock10b5-1 | -20,000 | $23.52 | $470k | 43,298 | Feb 11, 2026 |
| Feb 11, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stock10b5-1 | -20,000 | $25.20 | $504k | 43,298 | Feb 11, 2026 |
| Feb 9, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 405,000 | Feb 11, 2026 |
| Feb 10, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 385,000 | Feb 11, 2026 |
| Feb 11, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 365,000 | Feb 11, 2026 |
Related signals
Other insiders at Pulse Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,025 shares | +98% | |
| 38Weak | PLSEbuy Pulse Biosciences, Inc. | Liane Rae Teplitsky Chief Operating Officer | $100k 2,070 shares | - | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 47Moderate | Pulse Biosciences, Inc. | Robert W Duggan director, owner | $13M 660,233 shares | +1% | |
| 59Moderate | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | - | |
| 61Notable | Pulse Biosciences, Inc. | Paul A Laviolette Chief Executive Officer | $295k 15,000 shares | +1773% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $118k 5,000 shares | -10% | |
| 25Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $1.4M 60,000 shares | -95% | |
| 0Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $85k 4,600 shares | -10% | |
| 14Weak | Pulse Biosciences, Inc. | Kevin Patrick Danahy Chief Commercial Officer | $377k 20,400 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.